Article info

Download PDFPDF

Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case–control study
Free

Authors

  1. Correspondence to Dr Giustino Parruti, Infectious Diseases Unit, Pescara Hospital, Pescara 65124, Italy; parrutig{at}gmail.com
View Full Text

Citation

Potere N, Di Nisio M, Cibelli D, et al
Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case–control study

Publication history

  • Received June 5, 2020
  • Revised June 28, 2020
  • Accepted June 29, 2020
  • First published July 9, 2020.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.